Spots Global Cancer Trial Database for goserelin
Every month we try and update this database with for goserelin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer | NCT01723774 | Breast Neoplasm... | PD0332991 Anastrozole Goserelin Surgery (standa... Tumor biopsy | 18 Years - | Washington University School of Medicine | |
| Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients | NCT02430103 | Breast Cancer | Goserelin 3.6 M... | 18 Years - 45 Years | Peking University People's Hospital | |
| Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | NCT01942135 | Metastatic Brea... | Palbociclib Fulvestrant Placebo Fulvestrant | 18 Years - | Pfizer | |
| Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer | NCT02430480 | Prostate Cancer | Goserelin Enzalutamide mpMRI | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | NCT05163106 | Breast Cancer HER2-negative B... ER-positive Bre... Locally Advance... Luminal A Breas... Luminal B Breas... | Letrozole 2.5mg... Goserelin | 18 Years - | University Hospital, Akershus | |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | NCT05050084 | Prostate Adenoc... | Bicalutamide Buserelin Darolutamide Degarelix Flutamide Goserelin Histrelin Leuprolide Radiation Thera... Relugolix Triptorelin | 18 Years - | NRG Oncology | |
| PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY | NCT03423199 | Breast Neoplasm... | Palbociclib Placebo Tamoxifen Goserelin | 18 Years - | National Cancer Center, Japan | |
| Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women | NCT00912548 | Breast Cancer | goserelin tamoxifen | 18 Years - 45 Years | Korean Breast Cancer Study Group | |
| Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women | NCT02914158 | Breast Cancer | Goserelin Tamoxifen Aromatase Inhib... Leuprolide | - 35 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC | NCT05513365 | Salivary Duct C... | Goserelin 10.8 ... Bicalutamide 50... Dutasteride 0.5... | 18 Years - | Radboud University Medical Center | |
| Bipolar Androgen-based Therapy for Prostate Cancer (BAT) | NCT01750398 | Recurrent Prost... | Testosterone cy... Goserelin Leuprolide | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer | NCT00833248 | Prostate Cancer | Degarelix Goserelin Bicalutamide | 18 Years - | Ferring Pharmaceuticals | |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | NCT00028769 | Prostate Cancer | bicalutamide estramustine etoposide flutamide goserelin leuprolide nilutamide paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | NCT01377389 | Prostate Cancer | Ipilimumab Leuprolide Goserelin Degarelix | 18 Years - | M.D. Anderson Cancer Center | |
| CMAB vs IMAB in Metastatic Prostate Cancer | NCT00255268 | Metastatic Pros... | Goserelin Bicalutamide | 18 Years - | AstraZeneca | |
| Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer | NCT02483767 | Breast Cancer | goserelin standard chemot... | 18 Years - 45 Years | Peking Union Medical College Hospital | |
| External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer | NCT00388804 | Prostate Cancer | Radiation Thera... Bicalutamide Leuprolide Goserelin Flutamide Questionnaire | - | M.D. Anderson Cancer Center | |
| Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer | NCT00631527 | Prostate Cancer | Leuprolide Goserelin Sunitinib Malat... Casodex Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | NCT00771017 | Prostate Cancer | GVAX prostate c... bicalutamide goserelin leuprolide acet... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer | NCT00651326 | Prostate Cancer | bicalutamide buserelin flutamide goserelin leuprolide acet... neoadjuvant the... quality-of-life... radiation thera... Docetaxel | 18 Years - | Canadian Cancer Trials Group | |
| Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer | NCT01205685 | Hormone-sensiti... | OSI-906 Erlotinib Letrozole Goserelin | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population | NCT01744366 | Prostate Cancer | Degarelix Goserelin | 18 Years - | Ferring Pharmaceuticals | |
| Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | NCT00771017 | Prostate Cancer | GVAX prostate c... bicalutamide goserelin leuprolide acet... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate | NCT04736108 | Prostate Cancer | Abiraterone ace... Prednisolone Goserelin | 18 Years - | West China Hospital | |
| Bipolar Androgen-based Therapy for Prostate Cancer (BAT) | NCT01750398 | Recurrent Prost... | Testosterone cy... Goserelin Leuprolide | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Everolimus trIal for Advanced prememopausaL Breast Cancer Patients | NCT02313051 | Metastatic Brea... | Everolimus Goserelin Letrozole | 18 Years - | ChineseAMS | |
| Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer | NCT00002889 | Prostate Cancer | flutamide goserelin leuprolide acet... low-LET photon ... | 30 Years - | Alliance for Clinical Trials in Oncology | |
| Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia | NCT05800197 | Breast Cancer Neoadjuvant End... | Tamoxifen 20mg Anastrozole 1mg Letrozole 2.5mg Goserelin Triptorelin | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | NCT02789878 | Prostate Cancer | Goserelin Prednisone Abiraterone Apalutamide | 18 Years - 80 Years | Instituto do Cancer do Estado de São Paulo | |
| Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women | NCT02914158 | Breast Cancer | Goserelin Tamoxifen Aromatase Inhib... Leuprolide | - 35 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer | NCT03628066 | Breast Cancer | Letrozole Palbociclib Goserelin Oncotype DX Bre... | 18 Years - | NSABP Foundation Inc | |
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | NCT00295646 | Breast Cancer | tamoxifen anastrozole zoledronic acid goserelin | 19 Years - 59 Years | Austrian Breast & Colorectal Cancer Study Group | |
| Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer | NCT02483767 | Breast Cancer | goserelin standard chemot... | 18 Years - 45 Years | Peking Union Medical College Hospital | |
| International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer | NCT01252693 | Prostate Cancer | Ozarelix Goserelin | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Tecemotide (L-BLP25) in Prostate Cancer | NCT01496131 | Prostate Cancer | Radiation thera... Goserelin Cyclophosphamid... Tecemotide (L-B... | 18 Years - | EMD Serono | |
| Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | NCT01942135 | Metastatic Brea... | Palbociclib Fulvestrant Placebo Fulvestrant | 18 Years - | Pfizer | |
| Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer | NCT02430480 | Prostate Cancer | Goserelin Enzalutamide mpMRI | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer | NCT02907918 | Breast Cancer Cancer of Breas... Breast Carcinom... | Palbociclib Letrozole Trastuzumab Goserelin Breast surgery Research tumor ... Research bone m... Research blood ... Research blood ... Blood for detec... | 18 Years - | Washington University School of Medicine | |
| Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer | NCT00769795 | Prostate Cancer | IMC-A12 Bicalutamide Goserelin | 18 Years - | University of Washington | |
| Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer | NCT00003653 | Prostate Cancer | bicalutamide buserelin cyproterone ace... flutamide goserelin leuprolide acet... nilutamide | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | NCT01989780 | Metastatic Brea... | Paclitaxel Bevacizumab Letrozole Anastrozole Exemestane Fulvestrant Goserelin leuprorelin | 20 Years - 75 Years | Japan Breast Cancer Research Group | |
| A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer | NCT01964170 | Prostate Cancer | degarelix Goserelin | 20 Years - | Astellas Pharma Inc | |
| Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients | NCT02430103 | Breast Cancer | Goserelin 3.6 M... | 18 Years - 45 Years | Peking University People's Hospital | |
| Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | NCT03007979 | Breast Cancer Breast Carcinom... Cancer of Breas... Malignant Tumor... | Palbociclib Letrozole Fulvestrant Optional resear... Goserelin Research blood ... Circulating tum... Tumor biopsy (o... | 18 Years - | Washington University School of Medicine | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University | |
| Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea | NCT02132390 | Breast Cancer Chemotherapy In... Ovarian Functio... | Goserelin Toremifene | 18 Years - 45 Years | Peking Union Medical College Hospital | |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC | NCT05513365 | Salivary Duct C... | Goserelin 10.8 ... Bicalutamide 50... Dutasteride 0.5... | 18 Years - | Radboud University Medical Center | |
| Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer | NCT01013506 | Breast Cancer | IGF-1R inhibito... erlotinib hydro... goserelin letrozole | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | NCT02333370 | Hormone Recepto... | LEE011 Letrozole Tamoxifen Fulvestrant goserelin | 18 Years - | Novartis | |
| Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea | NCT02132390 | Breast Cancer Chemotherapy In... Ovarian Functio... | Goserelin Toremifene | 18 Years - 45 Years | Peking Union Medical College Hospital | |
| Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients | NCT00884273 | Prostate Cancer | Degarelix Goserelin Bicalutamide | 18 Years - | Ferring Pharmaceuticals | |
| Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer | NCT01013506 | Breast Cancer | IGF-1R inhibito... erlotinib hydro... goserelin letrozole | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women | NCT01266213 | Metastatic Brea... Estrogen Recept... Breast Cancer N... | Fulvestrant plu... Anastrozole plu... Goserelin | - 55 Years | Samsung Medical Center | |
| Neoadjuvant Treatment of Breast Cancer | NCT05131893 | Breast Cancer | Tamoxifen Goserelin Letrozole 2.5Mg... Epirubicin cyclophosphamid... Docetaxel paclitaxel trastuzumab pertuzumab Capecitabine | 18 Years - 100 Years | National Institute of Oncology, Hungary | |
| Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | NCT05163106 | Breast Cancer HER2-negative B... ER-positive Bre... Locally Advance... Luminal A Breas... Luminal B Breas... | Letrozole 2.5mg... Goserelin | 18 Years - | University Hospital, Akershus | |
| A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer | NCT01964170 | Prostate Cancer | degarelix Goserelin | 20 Years - | Astellas Pharma Inc | |
| Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer | NCT00769795 | Prostate Cancer | IMC-A12 Bicalutamide Goserelin | 18 Years - | University of Washington | |
| One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population | NCT01744366 | Prostate Cancer | Degarelix Goserelin | 18 Years - | Ferring Pharmaceuticals | |
| Zoladex Plus Tamoxifen in Breast Cancer | NCT00827307 | Mammography Estrogen Lipemia Endometrium Ultrasonography | tamoxifen Goserelin | 18 Years - 50 Years | Zhejiang Cancer Hospital | |
| Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | NCT03671330 | Breast Cancer | Ribociclib Plac... Ribociclib NSAI: Letrozole... Letrozole Goserelin | 18 Years - 60 Years | Novartis | |
| Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer | NCT04060043 | Prostate Cancer | Goserelin Aceta... | 18 Years - | CMX Research | |
| MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer | NCT01240928 | Metastatic Brea... | MSK-2206 Exemestane Goserelin | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | NCT01989780 | Metastatic Brea... | Paclitaxel Bevacizumab Letrozole Anastrozole Exemestane Fulvestrant Goserelin leuprorelin | 20 Years - 75 Years | Japan Breast Cancer Research Group | |
| Micro RNAs to Predict Response to Androgen Deprivation Therapy | NCT02366494 | Prostate Cancer | Bicalutamide Leuprolide Goserelin Triptorelin Docetaxel Abiraterone Apalutamide Enzalutamide | 21 Years - 85 Years | Medical College of Wisconsin | |
| Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer | NCT00498901 | Breast Cancer | goserelin letrozole leuprolide acet... conventional su... | 18 Years - | University of Washington | |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | NCT02333370 | Hormone Recepto... | LEE011 Letrozole Tamoxifen Fulvestrant goserelin | 18 Years - | Novartis | |
| Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | NCT05720260 | Premenopausal B... Metastatic Brea... ER Positive Bre... | Goserelin Fulvestrant Capivasertib Durvalumab | 20 Years - | National Taiwan University Hospital | |
| Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer | NCT04478266 | Breast Cancer | Amcenestrant-ma... SAR439859 Palbociclib Letrozole Goserelin Letrozole-match... | 18 Years - | Sanofi | |
| Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer | NCT04060043 | Prostate Cancer | Goserelin Aceta... | 18 Years - | CMX Research | |
| Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer | NCT00498901 | Breast Cancer | goserelin letrozole leuprolide acet... conventional su... | 18 Years - | University of Washington | |
| Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial | NCT06378866 | Recurrent Castr... Stage IVB Prost... Recurrent Prost... Castration-resi... | Abiraterone Apalutamide Biospecimen Col... Bone Scan Computed Tomogr... Darolutamide Degarelix Enzalutamide Goserelin Histrelin Leuprolide Magnetic Resona... Patient Observa... Positron Emissi... Prednisone Questionnaire A... Relugolix Stereotactic Bo... Triptorelin | 18 Years - | Mayo Clinic | |
| PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer | NCT02917005 | Metastatic Brea... | Palbociclib Exemestane Goserelin | 18 Years - | Africa Middle East Cancer Intergroup | |
| Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer | NCT00831233 | Prostate Cancer | Degarelix Goserelin Bicalutamide | 18 Years - | Ferring Pharmaceuticals | |
| Neoadjuvant Goserelin for Triple Negative Breast Cancer | NCT03444025 | Breast Cancer T... | Goserelin | 18 Years - 60 Years | Kasr El Aini Hospital | |
| Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy | NCT00439751 | Prostate Cancer | Goserelin Aceta... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | NCT03860987 | Castrate Sensit... | goserelin Enzalutamide Abiraterone 18F-DCFPyL Prednisone Radical Prostat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer | NCT03822468 | Breast Cancer | Ribociclib Anastrozole Letrozole Goserelin | 18 Years - | Novartis | |
| Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate | NCT04736108 | Prostate Cancer | Abiraterone ace... Prednisolone Goserelin | 18 Years - | West China Hospital | |
| Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer | NCT00002633 | Prostate Cancer | bicalutamide buserelin flutamide goserelin leuprolide acet... nilutamide orchiectomy radiation thera... | - 79 Years | Canadian Cancer Trials Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
